RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

NCT04620733 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

193

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Biliary Cholangitis

Interventions

DRUG: Seladelpar 10 mg
DRUG: Placebo
DRUG: Seladelpar 5 mg

Sponsor

Gilead Sciences